Latest Breaking News On - நாள்பட்ட லுகேமியா - Page 1 : comparemela.com

As pointed out by Tiacci and colleagues, the BRAF V600E mutation is known to be the causal genetic event of HCL. Vemurafenib is a BRAF inhibitor, and while two studies showed it had activity in patients with refractory or relapsed HCL, relapses were common, with one study showing a median relapse-free survival of 9 months after the end of treatment. Rituximab is myelotoxic and may complement intracellular BRAF inhibition in killing leukemic cells by means of a different mechanism, the authors explained. This phase II single-center trial included 30 patients with refractory or relapsed HCL. Patients had previously received a median of three therapies. The study treatment regimen consisted of 8 weeks of oral vemurafenib (960 mg twice daily) and eight intravenous rituximab infusions (375 mg/m

United statesMichael greverEnrico tiacciMike bassettUniversity of perugiaOhio state university in columbusHairy cell leukemia foundationLymphoma societyNew england journalOhio state universityEngland journalEnglj medHairy cell leukemiaChronic leukemiaஒன்றுபட்டது மாநிலங்களில்மைக் பாசெட்